Vivo Bio Tech has informed about Statement of Investor Grievance Redressal Report for the quarter ended 30th September, 2017 in compliance with Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.